General Callout
Nunc dolor esse suscipit eros eros ullamco dolor. Duis velaliquam sunt urna, tempuribud doming quis, laboris ultricies ultricies urna laboris. Nostrud pulvinar nostrud elit sunt ex exercitation magna tempuribud laboris ea ex nunc sed exercitation ea laboris dignissim.
Accordion
Quis harmud ea commodo voluptate dolor urna providerent tempor amet dignissim velit consectetur harmud sint doming, urna magna velit sed commodo urna sint sunt nunc. Nunc consectetur laboris harmud dolore exercitation sed magna laboris nulla velit velaliquam ultricies. Dignissim adipiscing, sed duis ultricies sint voluptate providerent nunc nisi.
Heading 1
Pariatur aliquip quis doming sint eros sit nulla consectetur velit quis consectetur ea dolore quis, eros voluptate commodo quis doming sint aliquip esse tempuribud quis velit ut ut aliquip ex quis, ullamco eu in. Nisi nulla amet quis tempor tempuribud aliquip. Adipiscing nostrud eu fugiat, duis quis sunt eu, providerent sed quis pariatur velit amet dolore in.
Heading 2
Pariatur aliquip quis doming sint eros sit nulla consectetur velit quis consectetur ea dolore quis, eros voluptate commodo quis doming sint aliquip esse tempuribud quis velit ut ut aliquip ex quis, ullamco eu in. Nisi nulla amet quis tempor tempuribud aliquip. Adipiscing nostrud eu fugiat, duis quis sunt eu, providerent sed quis pariatur velit amet dolore in.
Call to action
Esse suscipit in eros ea sed voluptate dolore, harmud nisi, dolore ultricies fugiat amet doming ut sint ut adipiscing. Sit velit velaliquam ex nunc ut voluptate
Status:
Concluded with an LOI
Manufacturer:
Jazz Pharmaceuticals Canada Inc.
Indication:
Seizures associated with Tuberous Sclerosis Complex (TSC)
Last updated March 12, 2025
Status:
Concluded with an LOI
Manufacturer:
Jazz Pharmaceuticals Canada Inc.
Indication:
Dravet Syndrome (DS)
Last updated March 12, 2025
Status:
Concluded with an LOI
Manufacturer:
Jazz Pharmaceuticals Canada Inc.
Indication:
Lennox-Gastaut Syndrome (LGS)
Last updated March 12, 2025
Status:
Concluded with an LOI
Manufacturer:
Celltrion Healthcare Canada Ltd.
Indication:
Multiple Indications
Last updated March 10, 2025
Status:
Concluded with an LOI
Manufacturer:
Celltrion Healthcare Canada Ltd.
Indication:
Multiple Indications
Last updated March 10, 2025
Status:
Concluded with an LOI
Manufacturer:
Regeneron
Indication:
Non-small cell lung cancer (NSCLC) expressing PD-L1 in ? 50% of tumour cells (Tumour Proportion Score [TPS] ? 50%), as determined by a validated test, with no EGFR, ALK or ROS1 aberrations, first-line treatment of adult patients who have locally advanced NSCLC who are not candidates for surgical resection or definitive chemoradiation, or metastatic NSCLC
Last updated March 3, 2025
Status:
Concluded with an LOI
Manufacturer:
Regeneron
Indication:
For the treatment of patients with locally advanced basal cell carcinoma (BCC) previously treated with a hedgehog pathway inhibitor
Last updated March 3, 2025
Status:
Concluded with an LOI
Manufacturer:
Regeneron
Indication:
In combination with platinum-based chemotherapy for the first-line treatment of adult patients with non-small cell lung cancer (NSCLC) whose tumors have no epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK) or c-ROS oncogene 1 (ROS1) aberrations and is locally advanced where patients are not candidates for surgical resection or definitive chemoradiation, or metastatic NSCLC
Last updated March 3, 2025
Status:
Concluded with an LOI
Manufacturer:
Pfizer Canada ULC
Indication:
Multiple Indications
Last updated February 28, 2025
Axberi/Axberi HP (enoxaparin sodium solution for injection)
Status:
Concluded with an LOI
Manufacturer:
Baxter Corporation
Indication:
Thrombosis and cardiovascular conditions (prevention or treatment)
Last updated February 28, 2025